Home › Funds › Harold Davidson & Associates Inc. › ABT
Harold Davidson & Associates Inc. position in ABT
ABBOTT LABORATORIES · Health Care
Harold Davidson & Associates Inc. reported holding 8,619 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$852K, representing 0.35% of its reported portfolio and ranking #41 among its reported holdings. Harold Davidson & Associates Inc. has disclosed ABT holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
Last updated: 2026-10-30 · Source: SEC EDGAR Form 13F-HR
How Harold Davidson & Associates Inc.'s ABT position evolved
Harold Davidson & Associates Inc. first disclosed a stake in ABT in Q4 2024 at 11,246 shares (US$1.3M). The position peaked in Q3 2025 at 10,945 shares, worth US$1.5M. Across 8 filings, Harold Davidson & Associates Inc. increased the stake 1 time(s), trimmed it 6 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 8,619 shares valued at US$852K — a reduction of -430 shares quarter over quarter.. Notable position changes include a 27% increase in Q3 2025 (shares fell 6% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 11.25K | $1.27M | New |
| Q1 2025 | 10.88K | $1.44M | Reduce |
| Q2 2025 | 8.60K | $1.17M | Reduce |
| Q3 2025 | 10.95K | $1.47M | Add |
| Q4 2025 | 9.96K | $1.25M | Reduce |
| Q1 2026 | 9.48K | $973.72K | Reduce |
| Q2 2026 | 9.05K | $821.11K | Reduce |
| Q3 2026 | 8.62K | $851.82K | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ABT and 13F data
ABT (ABBOTT LABORATORIES) is a Health Care company. 20 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ABT
- Vanguard Group 175.56M sh · $22.00B · Q4 2025
- Charles Schwab Investment Management 59.67M sh · $5.41B · Q2 2026
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC 59.67M sh · $5.41B · Q2 2026
- Sixth Street Partners Management Company, L.P. 59.67M sh · $5.41B · Q2 2026
- Capital Research Global Investors 36.91M sh · $3.35B · Q2 2026
- Capital Research Global Investors 36.91M sh · $3.35B · Q2 2026
- Capital International Investors 34.65M sh · $3.15B · Q2 2026
- Deutsche Bank AG 16.71M sh · $1.52B · Q2 2026
More on Harold Davidson & Associates Inc.
FAQ
How long has Harold Davidson & Associates Inc. held ABT?
Harold Davidson & Associates Inc. has disclosed ABT holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
What is Harold Davidson & Associates Inc.'s current position in ABT?
As of Q3 2026, Harold Davidson & Associates Inc. holds 8.62K shares of ABT (ABBOTT LABORATORIES), valued at $851.82K, representing 0.35% of its reported portfolio and ranking #41.
Has Harold Davidson & Associates Inc. been buying or selling ABT?
In the latest 13F filing (Q3 2026), Harold Davidson & Associates Inc. reduced its position in ABT. The position peaked in Q3 2025 at 10.95K shares.
Which other funds hold ABT?
Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 20 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.